According to Bohui Innovation's announcement, intravenous human immunoglobulin declared by its holding subsidiary Guangdong Weilun received the “Drug Clinical Trial Approval Notice” from the State Drug Administration and agreed to conduct clinical trials. The drug's acceptance number is CXSL2500861 and is suitable for primary/secondary immunoglobulin deficiency diseases, autoimmune diseases, etc. After approval, clinical research must be carried out as required and approved before it can be marketed. However, drug development risks are high and the cycle is long. This approval is a phased achievement and will not have a significant impact on the company's recent performance.

According to Bohui Innovation's announcement, intravenous human immunoglobulin declared by its holding subsidiary Guangdong Weilun received the “Drug Clinical Trial Approval Notice” from the State Drug Administration and agreed to conduct clinical trials. The drug's acceptance number is CXSL2500861 and is suitable for primary/secondary immunoglobulin deficiency diseases, autoimmune diseases, etc. After approval, clinical research must be carried out as required and approved before it can be marketed. However, drug development risks are high and the cycle is long. This approval is a phased achievement and will not have a significant impact on the company's recent performance.